{
    "clinical_study": {
        "@rank": "67287", 
        "arm_group": [
            {
                "arm_group_label": "Algeron", 
                "arm_group_type": "Experimental", 
                "description": "Algeron at a dose of 1.5 \u00b5g/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)"
            }, 
            {
                "arm_group_label": "PegIntron", 
                "arm_group_type": "Active Comparator", 
                "description": "PegIntron at a dose of 1.5 \u00b5g/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to demonstrate the noninferiority of Algeron in combination with\n      ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic\n      hepatitis C in HIV-1 infected patients"
        }, 
        "brief_title": "An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in HIV-1 Infected Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis", 
            "Hepatitis C", 
            "Coinfection HCV and HIV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The course of treatment in both groups shall be 12 weeks, and efficacy analysis, i.e. rate\n      of rapid (after the 4th week) and early (after the 12th week) virologic response will be\n      based on PCR data. For patients with treatment failure after the 12th week the antiviral\n      therapy shall be discontinued. All patients who require further anti-viral treatment will\n      receive a combination treatment with Algeron / PegIntron and ribavirin for another 36 weeks.\n      Sustained virologic response will be assessed 24 weeks after last dose of study treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed Informed Consent Form.\n\n          -  Chronic hepatitis C (genotypes 1\u0430, 1b, 2, 3, 4)  confirmed by positive result of HCV\n             RNA during > 6 months before screening visit or accompanied with increase in ALT\n             level > 6 months before screening visit.\n\n          -  Confirmed HIV-1 infection based on ELISA and immune blotting results.\n\n          -  Clinically sustained phase of HIV-1 infection with absence of active opportunistic\n             HIV-associated diseases  for at least 30 calendar days before inclusion in the study.\n\n          -  Level of CD4+-lymphocytes is not less than 500 cells/mm3 for patients not requiring\n             highly active antiretroviral therapy and which will not be assigned to antiretroviral\n             therapy during the study period.\n\n          -  For patients receiving sustained highly active antiretroviral therapy for not less\n             than 12 weeks and planning to continue comply with this treatment regimen during the\n             following 24 weeks, level of CD4+-lymphocytes \u2265300 cells/mm3, HIV RNA \u226450 copies/ml.\n\n          -  Men and women aged 18 to 70 inclusively.\n\n          -  Body mass index in the range of 18 - 30 kg/m2 inclusively .\n\n          -  Preserved protein-synthetizing liver function (INR < 1.7, albumin > 35 g/l).\n\n          -  Absence of signs of hepatic encephalopathy and ascites according to clinical\n             examination and ultrasound examination.\n\n          -  Patients with preserved child-bearing potential and their partners agree to use\n             barrier method of contraception during the whole period of therapy and during 7\n             months after the treatment completion.\n\n          -  Documentary confirmed results of liver elastography (fibroscan) during last year\n             before enrollment in the study or patient agreement to undergo this examination\n             during screening.\n\n        Exclusion Criteria:\n\n          -  Intolerance of alfa-interferons, ribavirin or any components of tested drug product\n             based on medical history.\n\n          -  Presence of hepatitis B, A, E markers.\n\n          -  Presence of documentary confirmed clinically significant concurrent liver diseases\n             (alcoholic liver cirrhosis, drug-induced liver cirrhosis, autoimmune hepatitis,\n             hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis, biliary cirrhosis\n             etc.).\n\n          -  Past history of HCV treatment with IFN alfa or pegylated IFN alfa.\n\n          -  For patients receiving sustained highly active antiretroviral therapy - presence of\n             nevirapine, stavudine, zidovudine, didanosine in treatment regimen.\n\n          -  Use of injectable and non-injectable interferons alfa/ interferon inducers for any\n             indication (except for hepatitis C), radiotherapy, cytotoxic chemotherapy for one\n             month prior to inclusion in the study.\n\n          -  Cholestic hepatitis (level of direct bilirubin, alkaline phosphatase, GGT, exceeding\n             UNL in > 5 times).\n\n          -  Decompensated liver cirrhosis confirmed with results of laboratory analyses\n             (Child-Pugh class B, C) or ultrasound examination.\n\n          -  Any documentary confirmed autoimmune diseases (such as Crohn's disease, ulcerative\n             colitis, systemic lupus erythemathosus, idiopathic thrombocytopenic purpura,\n             scleroderma, autoimmune hemolytic anemia, severe psoriasis).\n\n          -  Deviations of hematologic (hemoglobin less than lower normal limit; neutrophils < 1.5\n             x 109/l; thrombocytes < 90 x 109/ l) and biochemical (creatinine level > 1.5 times\n             higher UNL , ALT is > 10 times higher UNL ) parameters.\n\n          -  Documentary confirmed diagnosis of hemoglobinopathy (for example, thalassemia,\n             sickle-cell anemia).\n\n          -  Severe depression, schizophrenia, any other mental disorders which according to the\n             investigator are contraindications for antiviral treatment.\n\n          -  Epilepsy and/or central nervous system disorder.\n\n          -  Disorder of thyroid function (level of TSH out of the normal range).\n\n          -  Documentary confirmed or suspected hepatocellular carcinoma based on the results of\n             alfa-fetoprotein (AFP) assay \u2265 UNL.\n\n          -  Antinuclear antibodies (ANA) titer measured at screening is not less than 1:640 or\n             documentary confirmed signs of autoimmune hepatitis based on the results of biopsy.\n\n          -  Documentary confirmed malignant neoplasms.\n\n          -  Documentary confirmed lung diseases associated with respiratory failure.\n\n          -  Treatment of HIV-1 with immunotherapeutic vaccines within 90 days prior to screening.\n\n          -  Necessity in assignment of antimicobacterial therapy.\n\n          -  Pregnancy, lactation period.\n\n          -  Documentary confirmed retinopathy (for example, cytomegalovirus retinitis, macular\n             degeneration).\n\n          -  Severe concurrent diseases (for example, severe arterial hypertension, sever coronary\n             heart disease, heart failure, decompensated diabetes mellitus and other) which are\n             contraindications for antiviral therapy according to the investigator opinion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103439", 
            "org_study_id": "BCD-016-4"
        }, 
        "intervention": [
            {
                "arm_group_label": "Algeron", 
                "description": "1.5 \u00b5g/kg of body weight subcutaneously, once a week", 
                "intervention_name": "Algeron", 
                "intervention_type": "Drug", 
                "other_name": "Cepeginterferon alfa-2b"
            }, 
            {
                "arm_group_label": "PegIntron", 
                "description": "1.5 \u00b5g/kg of body weight subcutaneously, once a week", 
                "intervention_name": "PegIntron", 
                "intervention_type": "Drug", 
                "other_name": "peginterferon alfa-2b"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2b", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatitis C", 
            "Cepeginterferon alfa", 
            "Peginterferon", 
            "Treatment"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kazan", 
                        "country": "Russian Federation", 
                        "state": "Republic of Tatarstan", 
                        "zip": "420097"
                    }, 
                    "name": "State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nizhny Novgorod", 
                        "country": "Russian Federation", 
                        "zip": "603005"
                    }, 
                    "name": "State Institution of Nizhny Novgorod region \"Regional Center for Prevention and Control of AIDS and other infectious diseases\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sankt-Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "190103"
                    }, 
                    "name": "State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saratov", 
                        "country": "Russian Federation", 
                        "zip": "410012"
                    }, 
                    "name": "State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State University of medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vladivostok", 
                        "country": "Russian Federation", 
                        "zip": "690002"
                    }, 
                    "name": "State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Volgograd", 
                        "country": "Russian Federation", 
                        "zip": "400040"
                    }, 
                    "name": "State Healthcare Institution \"Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases\""
                }
            }
        ], 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC \"BIOCAD\", Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in HIV-1 Infected Patients", 
        "overall_official": [
            {
                "affiliation": "State Institution of Nizhny Novgorod region \"Regional Center for Prevention and Control of AIDS and other infectious diseases\"", 
                "last_name": "Gregory Moshkovich, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan", 
                "last_name": "Firaya Nagimova, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Healthcare Institution \"Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases\"", 
                "last_name": "Oleg Kozyrev, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State  University of medicine", 
                "last_name": "Andrey Shuldyakov, M.D., PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department", 
                "last_name": "Vadim Rassokhin, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation", 
                "last_name": "Lidia Sklar, M.D., PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of randomized patients achieving early virologic response (EVR) - negative PCR result for HCV RNA (< 15 IU/ml) or \u2265 2log10 decrease of viral load after 12 weeks of study treatment", 
            "measure": "EVR", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103439"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of randomized patients achieving rapid virologic response (RVR) - negative PCR result for HCV RNA (< 15 IU/ml) after 4 weeks of treatment", 
                "measure": "RVR", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Proportion of randomized patients achieving sustained virologic response (SVR) - negative PCR result for HCV RNA (< 15 IU/ml) 24 weeks after last dose of study treatment", 
                "measure": "SVR (24)", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks after last dose of study treatment"
            }, 
            {
                "description": "Proportion of randomized patients achieving end-of-treatment response (EOT) -undetectable HCV RNA (< 15 IU/ml)  after 48 weeks of treatment", 
                "measure": "EOT", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks of treatment"
            }, 
            {
                "description": "Proportion of patients who have ALT level \u2264 than upper normal level after 12 weeks of treatment,at the end of treatment (after 48 weeks of treatment) and 24 weeks after last dose of study treatment", 
                "measure": "Biochemical Response", 
                "safety_issue": "Yes", 
                "time_frame": "12, 48 weeks of treatment and 24 weeks after last dose of study treatment"
            }, 
            {
                "description": "Proportion of patients with decreased in fibrosis level by 1 level on the METAVIR score compared to screening data and in 24 weeks after treatment completion.", 
                "measure": "Histological Response", 
                "safety_issue": "Yes", 
                "time_frame": "screening data and in 24 weeks after treatment completion"
            }, 
            {
                "description": "Proportion of patients  in each groups with level of HCV RNA > 15 IU/ml after HCV RNA was not present or HCV RNA was increased by more than 1log10 from baseline at 4 or 12 or 24 weeks of treatment", 
                "measure": "Viral breakthrough", 
                "safety_issue": "Yes", 
                "time_frame": "screening data and at 4 or 12 or 24 weeks of treatment."
            }
        ], 
        "source": "Biocad", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biocad", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}